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Membrane modelAntimicrobial peptides (AMPs) are a class of broad-spectrum antibiotics known by their ability to disrupt bacte-
rialmembranes and their low tendency to induce bacterial resistance, arising as excellent candidates toﬁght bac-
terial infections. In this study we aimed at designing short 12-mer AMPs, derived from a highly effective and
broad spectrum synthetic AMP, MSI-78 (22 residues), by truncating this peptide at the N- and/or C-termini
while spanning its entire sequencewith 1 amino acid (aa) shifts. These designed peptideswere evaluated regard-
ing antimicrobial activity against selected gram-positive Staphylococcus strains and the gram-negative Pseudomo-
nas aeruginosa (P. aeruginosa).
The short 12-mer peptide CEM1 (GIGKFLKKAKKF) was identiﬁed as an excellent candidate to ﬁght P. aeruginosa
infections as it displays antimicrobial activity against this strain and selectivity, with negligible toxicity to mam-
malian cells even at high concentrations. However, in general most of the short 12-mer peptides tested showed a
reduction in antimicrobial activity, an effect that wasmore pronounced for gram-positive Staphylococcus strains.
Interestingly, CEM1 and a highly similar peptide differing by only one aa-shift (CEM2: IGKFLKKAKKFG), showed a
remarkably contrasting AMP activity. These two peptides were chosen for a more detailed study regarding their
mechanism of action, using several biophysical assays and simplemembranemodels thatmimic themammalian
and bacterial lipid composition.
We conﬁrmed the correlation between peptide helicity and antimicrobial activity and propose a mechanism of
action based on the disruption of the bacterial membrane permeability barrier.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Resistance to antibiotics is becoming a huge threat to public health [1],
thus newefforts arewarranted in order toﬁnd alternative therapeutic so-
lutions. Among these, antimicrobial peptides (AMPs) have beendescribed
as a promising new class of antibiotics and are nowadays considered the
most innovative anti-infective agents of the last decades [2–4].
AMPs are part of the innate immune system of several organisms
such as animals, plants, fungi, bacteria and viruses. These peptides areor indirectly by the authors.
aria Biomédica, Rua do Campo
982; fax: +351 22 6094567.usually 10–50 residues in length, highly cationic and have tendency to
formamphipathic structures,mostly due to the presence of separate hy-
drophobic and cationic domains [5,6]. Electrostatic attraction between
the cationic AMPs and anionic lipids of bacterial membranes promotes
the ﬁrst interactions. Most AMPs seem to kill bacteria by compromising
membrane integrity through direct binding to the lipid bilayer [7,8].
MSI-78 (commercially known as Pexiganan), a 22-mer AMP
developed for the treatment of infected diabetic foot ulcers [9,10], is
a broad spectrum AMP effective against over 3000 clinical isolates in-
cluding methicillin and gentamicin-resistant Staphylococcus aureus
(S. aureus) [9,11]. Practically no resistance has been associated to this
highly potent AMP [9,10,12].
MSI-78 has been described to disrupt bacterial membranes via a
toroidal-type pore formation upon binding to the membrane, forming
an antiparallel dimer of amphipathic helices [11]. The α-helical
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nized to favor AMP insertion in the microorganism membrane, as the
peptide amphipathic conformation allows the insertion of a well-
deﬁned hydrophobic sector into the lipid bilayer [13].
Although AMPs are promising antibiotic alternatives, they still pres-
ent a few drawbacks that compromise their therapeutic application
such as: low stability, high toxicity and high production costs [14].
Moreover the typical macromolecular size of AMP (20–40 amino acids
(aa)) limits the administration routes to topical and parenteral ones,
impairing a wide pharmaceutical applicability [15]. Therefore short
AMPs with high selectivity towards bacterial cells are desirable candi-
dates. The rational shortening of natural AMPs while maintaining anti-
microbial activity has been successfully done before with cecropin A-
Mellitin hybrids [16,17] and could be a strategy to tackle some of the
aforementioned drawbacks such as high toxicity and cost of production
while improving AMP therapeutic index.
With this work we aimed at the synthesis and study of new short
AMPs, namely, 12-mer fragments based on MSI-78, which were de-
signed to span the MSI-78 sequence with 1 aa shifts, while attempting
to preserve its remarkable features (Table 1).
Antimicrobial activity studies, using gram-positive Staphylococcus
strains and the gram-negative Pseudomonas aeruginosa (P. aeruginosa),
revealed differential efﬁciencies between the eleven 12-mer peptides
synthesized. Interestingly, two highly similar peptides differing by only
one aa-shift, showed a remarkably contrasting AMP activity, one being
the most effective peptide synthesized. These two peptides were chosen
for amore detailed study regarding their mechanism of action, using sev-
eral biophysical assays, and simple membrane models that mimic the
mammalian and bacterial lipid composition. In this study, large
unilamellar vesicles (LUVs) were used as membrane models since they
simulate an environment identical to biological membranes, i.e. they are
anisotropic and possess both lipophilic and hydrophilic regions. In addi-
tion, LUVs are comparatively more stable and can be easily quantiﬁed in
terms of lipid concentration, surface area and volume than model
systems such as lipid mixture suspensions, lipid ﬁlms, and small
unilamellar vesicles [18,19]. Since phosphatidylcholines are generally
the most abundant phospholipids in mammalian plasma membranes
[20], 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), a zwitterionic
phospholipid, was chosen [20,21] to mimic the neutral mammalian cell
membrane. On the other hand, phosphatidylglycerols are abundant in
bacterial membranes [22,23], therefore the 1,2-dimyristoyl-sn-glycero-
3-phosphoglycerol (DMPG), a negatively charged phospholipid, was
used as the membrane model of the bacterial cell membrane.2. Materials and methods
2.1. Reagents
Nα-Fmoc-protected amino acids, Rink amide AM resin, and 2-(1H-
Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphateTable 1
Amino acid sequences and selected features of synthetic peptides derived from MSI-78. The 12
Peptides Amino acid sequence Molecular weight
MSI-78 GIGKFLKKAKKFGKAFVKILKK 22 aa 2476
CEM1 GIGKFLKKAKKF 12 aa 1363,80
CEM2 IGKFLKKAKKFG 1363,73
CEM3 GKFLKKAKKFGK 1378,86
CEM4 KFLKKAKKFGKA 1392,73
CEM5 FLKKAKKFGKAF 1411,73
CEM6 LKKAKKFGKAFV 1363,73
CEM7 KKAKKFGKAFVK 1378,73
CEM8 KAKKFGKAFVKI 1363,67
CEM9 AKKFGKAFVKIL 1348,80
CEM10 KKFGKAFVKILK 1405,82
CEM11 KFGKAFVKILKK 1405,82(HBTU) for solid phase peptide synthesis (SPPS) were from
NovaBiochem-EMD4Biosciences (Darmstadt, Germany). N-ethyl-N,N-
diisopropylamine (DIEA), 1-hydroxybenzotriazole (HOBt), triﬂuoroacetic
acid (TFA), triisopropylsilane (TIS), piperidine and all solvents for SPPS
were from Sigma-Aldrich (St. Louis, MO, USA). Octadecylsilane stationary
phase 238TPB1520 for peptide puriﬁcation bymedium-pressure reverse-
phase liquid chromatography (MP-RPLC) was from Vydac (Hesperia, CA,
USA). The lipids, 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC)
and 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol (DMPG) were also
purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Hepes buffer
used in the biophysical experiments with LUV consisted of
10 mmol L−1 N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic
acid), the ionic strength was adjusted to 0.1 M with sodium chloride
and the pH to 7.4. In the circular dichroism (CD) experiments, the
buffer consisted of 10 mmol L−1 of sodium buffer and the ionic
strength was adjusted to 0.1 M with sodium ﬂuoride and the pH to
7.4. Hepes and sodium phosphate buffer were supplied by Sigma-
Aldrich Co. (St. Louis, MO, USA). All the other chemicals were pur-
chased from Merck.2.2. Peptide synthesis and characterization
All peptides (Table 1) were prepared as C-terminal amides by stan-
dard Fmoc/tBu SPPS on a Liberty1 Microwave (MW) Peptide Synthesizer
(CEM Corporation, Mathews, NC, USA) [24]. Brieﬂy, Rink amide AM resin
was pre-swelled for 15 min in N,N-dimethylformamide (DMF) and then
transferred into the MW-reaction vessel. The initial Fmoc deprotection
step was carried out using 20% piperidine in DMF containing 0.1 M
HOBt in two MW irradiation pulses: 30 s at 24 W plus 3 min at 28 W, in
both cases the temperature being no higher than 75 °C. The Fmoc-
protected C-terminal amino acid (Bachem, Switzerland) was then
coupled to the resin, using 5 molar equivalents (eq) of the Fmoc-
protected amino acid in DMF (0.2 M), 5 eq of 0.5 M HBTU/HOBt in DMF
and 10 eq of 2 M DIEA in N-methylpyrrolidone (NMP); the coupling
step was carried out for 5 min at 35 WMW irradiation, with maximum
temperature reaching 75 °C. The remaining amino acids were sequential-
ly coupled in the C→ N direction by means of similar deprotection and
coupling cycles. Following completion of sequence assembly, the peptides
were released from the resin with concomitant removal of side-chain
protecting groups, by a 3 h-acidolysis at room temperature using a TFA-
based cocktail containing TIS and water as scavengers (TFA/TIS/H2O
95:2.5:2.5 v/v/v). Crude products were puriﬁed by MP-RPLC to a purity
of at least 95%, as conﬁrmed by high-performance liquid chromatography
(HPLC) analysis on a Hitachi-Merck LaChrom Elite system equipped with
a quaternary pump, a thermostated (Peltier effect) automated sampler
and a diode-array detector (DAD). Pure peptides were quantiﬁed by
UV-absorption spectroscopy (Helios Gama, Spectronic Unicam) and
their molecular weights conﬁrmed to be as expected by electrospray ion-
ization/ion trap mass spectroscopy (ESI/IT MS; LCQ-DecaXP LC-MS sys-
tem, ThermoFinnigan).-mer peptides were designed to span MSI-78 by 1-residue shift.
Charge Total hydrophobic ratio Aliphatic index
+9 45% 93.18
+5 41% 73.33
+5 41% 73.33
+6 33% 40.83
+6 41% 49.17
+5 50% 49.17
+5 50% 73.33
+6 41% 40.83
+5 50% 73.33
+4 58% 105.83
+5 50% 97.50
+5 50% 97.50
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The Collection of Antimicrobial Peptides (CAMP) (http://www.
bicnirrh.res.in/antimicrobial/) was selected based on the number of in-
cluded peptide sequences, manual validation, variety of peptide origins
and prediction tools offer. Peptide sequence features analyzed were:
i) antimicrobial probability assessed by three different algorithms
&&(Random Forest (RF), Support Vector Machines (SVM) and Discrim-
inant Analysis (DA)); ii) overall net charge; iii) % hydrophobic residues
and iv) aliphatic index (the aliphatic index of a protein is deﬁned as the
relative volume occupied by aliphatic side chains, i.e., from alanine, va-
line, isoleucine, and leucine).
2.4. Microorganisms and growth conditions
Microorganisms tested in this study were the following: S. aureus
ATCC 33591 (methicillin resistant), S. aureus ATCC 25923, P. aeruginosa
ATCC 27853, Staphylococcus epidermidis (S. epidermidis) ATCC 35984 and
Candida albicans (C. albicans) DSM 1386. Bacteria were grown on
Trypticase Soy Agar (TSA) plates and Mueller–Hinton broth (MHB).
C. albicanswas grownon SabouraudMaltose agar (SMA), SabouraudDex-
trose broth (SDB) and RPMI 1640 with 3-(-morpholino)propanesulfonic
acid (MOPS), with L-glutamine and without sodium hydroxide.
2.5. Antimicrobial testing
Antimicrobial activitywas assessed byMinimal Inhibitory Concentra-
tion (MIC) and Minimal Bactericidal Concentration (MBC). The method
used to determine theMICwas the brothmicrodilution assay inmicroti-
ter plates, described by Wiegand and co-workers [25]. This method fol-
lows the guidelines of the two recognized organizations, CLSI and
EUCAST. Bacteria were pre-cultured on TSB overnight at 37 °C and
150 rpm. After washing with phosphate buffered saline (PBS) bacteria
were adjusted to approximately 2 × 105 CFU/mL in MHB and 99 μL was
transferred to a 96 well plate. C. albicanswas inoculated in SDB for 16 h
at 37 °C in an orbital shaker at 120 rpm.Afterwashingwith PBS cell num-
ber was adjusted to 1.6 × 106 cells/mL in RPMI medium using an im-
proved Neubauer hemocytometer and 99 μL was transferred to a 96
well plate. Polypropylenemicrotiter plates were used to prevent binding
of the peptides to thewalls of the wells. Peptide dilutions were prepared
in acetic acid/bovine serum albumin (BSA) solution and peptide concen-
trations tested ranged from 512 μg/mL to 0.015 μg/mL, adjusted accord-
ing to results obtained in preliminary experiments. The peptides were
tested in a ﬁnal volume of 110 μL.
The minimum bactericidal concentrations (MBC) were determined
by plating the content of the ﬁrst three wells where visible growth
was not observed.
2.6. Hemolysis assay on human red blood cells (RBC)
Human blood buffy coats were obtained from healthy volunteers
(Centro Hospitalar de São João, EPE, Porto, Portugal) and processed to
obtain RBC by centrifugation over density gradient with Histopaque-
1077 Sigma-Aldrich Co. (St. Louis, MO, USA) according to the
manufacturer's instructions. After removal of the plasma upper layer,
the lower layer containing RBCwas washed three times in PBS. The pu-
riﬁed RBC were diluted to 6–7 × 108 cells/mL in PBS and 99 μL was dis-
tributed in a 96 well polypropylene microtiter plate.
Peptide dilutions were prepared in acetic acid/BSA solution and the
range of peptide concentrations testedwent from512 μg/mL to 1 μg/mL.
After 1 h of incubation at 37 °C under 5% CO2, cells were centrifuged at
900 g for 10min and the supernatantwas transferred to a 96well plate.
The absorbance values of the released hemoglobin were determined at
450 nmusing amicroplate reader (SynergyMx, Biotek). Untreated cells
were used as negative control and cells treated with 0.2% Triton X-100
as positive controls. The percentage hemolysis was calculated as((sample absorbance−negative control absorbance) / (positive control
absorbance− negative control absorbance)) × 100.
2.7. Preparation of cell membrane models — large unilamellar vesicles
(LUVs)
Lipid ﬁlms were formed from chloroform solution of DMPC and
DMPG lipids, dried under a stream of nitrogen and left under reduced
pressure for a minimum of 45 min, to remove all traces of the organic
solvent. LUVs were prepared by the addition of the buffer, followed by
vortexing which yields multilamellar vesicles (MLV). Lipid suspensions
were equilibrated at 37.0 ± 0.1 °C for 30 min and extruded 10 times
through polycarbonate ﬁlters with a diameter pore of 100 nm to form
LUV as previously described [20].
2.8. Circular dichroism (CD) analysis
The secondary structure of the peptides CEM1, CEM2 and MSI-78,
was investigated using CD on a JASCO J-815 spectropolarimeter,
equipped with a temperature-controlled cuvette and controlled by the
Spectra manager software.
Peptide solutions were diluted in 10 mM sodium phosphate, pH 7.4,
100 mM sodium ﬂuoride to a concentration of 40 μMwith and without
5 mM DMPG or DMPC LUV, corresponding to peptide:lipid molar ratio
of 1:125.
Before the measurement all peptide solutions were incubated at
37 °C for 30 min.
Far-UV CD spectra were recorded between 195 and 260 nm using a
1 mm path length cuvette. CD spectra were acquired with a scanning
speed of 100 nm/min, an integration time of 1 s, and using a bandwidth
of 1 nm. The spectra were averaged over sixteen scans and corrected by
subtraction of the buffer signal.
The results are expressed as the mean residue ellipticity MRW, de-
ﬁned as MRW= obs (0.1MRW)/(lc), where obs is the observed ellipticity
inmillidegrees, MRW is themean residueweight, c is the concentration
in mg/mL and l is the light path length in cm.
The mean helix content (fH) was calculated according to Luo and
Baldwin [26]. Brieﬂy, fH is obtained from the MRW at 222 nm of each pep-
tide ( 222) according to the equation: fH= ( 222− C)/( H− C), where the
baseline ellipticities for random coil ( C) and complete helix ( H) are given
by: C=2220− 53T and H=(−44000+250T)(1− 3/N),where T is the
temperature in °C and N is the chain length in number of residues.
2.9. Hydrodynamic diameter and ζ-potential of LUV
The hydrodynamic diameters of the LUV in the absence and in the
presence of AMP were determined in BI-MAS dynamic light scattering
(DLS) instrument (Brookhaven Instruments, USA). Typically 6 runs
(2 min each) were performed and the cumulate analysis was applied
to scattering data to give effective diameters and polydispersity. The
ζ-potential was assessed through the determination of the electropho-
retic mobility using a ZetaPALS (Brookhaven Instruments Corporation).
For both determinations the temperature was maintained at 37.0 ±
0.1 °C, being the lipid concentration kept constant at 500 μM, and
AMP concentration ranged from 0–40 μM (0, 5, 10, 20 and 40 μM).
2.10. Biophysical properties of LUV
The effects of AMP (7.3 and 40 μM) on the biophysical parameters
(Tm and cooperativity) of DMPC and DMPG LUV (500 μM) were deter-
mined by DLS [27]. The count rate was obtained using a BI-MAS DLS in-
strument (Brookhaven Instruments, USA), containing a controlled
temperature cell holder. The samples were heated from 10.0 ± 0.1 °C
to 40.0 ± 0.1 °C with intervals of 1.0 ± 0.1 °C and with an equilibration
period of 2 min. At each temperature, six 2-min runs were performed.
Table 2
Determination of minimum inhibitory concentrations of MSI-78 and 12-mer derivatives
against selected microorganisms.
Microorganisms
Peptides S. aureus (MRSA) S. aureus S. epidermidis P. aeruginosa
MSI-78 16–32 8–16 0.5–1 (0.2–0.4) 0.5–1 (0.2–0.4)
CEM1 N512 512 32–64 (23–47) 4–8 (2.9–5.7)
CEM2 N512 N512 256 (194) 128–256 (94–194)
CEM3 N512 N512 256–512 N512
CEM4 N512 N512 512–N512 512
CEM5 N512 N512 256 64
CEM6 N512 N512 N512 256–512
CEM7 512 N512 N512 N512
CEM8 N512 N512 128–256 64–128
CEM9 128 256 128 32–64
CEM10 256 256 64–128 16–32
CEM11 256–512 256–512 64–128 16–32
MIC values are presented in μg/mL. Concentrations in μM are in parenthesis.
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tons detected per second) as the temperature changes, corresponds to
an alteration in the optical properties of the material studied (i.e., tran-
sition from initial state to another one) [28]. Data as the normalized
mean count rate versus temperature were collected and ﬁtted using:
rs ¼ rs1 þ p1T þ
rs2−rs1 þ p2t−p1T
1þ 10B 1=T−1=Tmð Þ ð1Þ
where rs is the average count rate, T is the temperature (°C), p1 and p2
correspond to the slopes of the straight lines at the beginning and at
the end of the plot, and rs1 and rs2 are the respective count rates
intercepting the values at the y axis [28]. From the experimental data
displayed, it was possible to calculate the cooperativity (B) and themid-
point of the phase transition, which corresponds to the temperature of
the gel-to-ﬂuid phase transition of the lipid (Tm) [28]. The Tmwas calcu-
lated from the slope and the inﬂection point of the data ﬁtted to sigmoid
curves of count rate (rs) versus temperature (T) [27].
3. Results
3.1. Peptide design
The eleven MSI-78-based 12-mer peptides synthesized are de-
scribed in Table 1. The 12-mer length was chosen as optimal regarding
biological function as, while short, it still allows peptide folding as am-
phipathic α-helices, as occurs with the lead peptide MSI-78 when
exerting its antimicrobial action [11].
In order to have a preliminary insight on the overall impact of the
truncations on the antimicrobial properties of the 12-mers, AMP predic-
tions and particular structure properties that have been related to anti-
microbial activity were analyzed using the AMP prediction tools of
CAMP. According to prediction outcomes all CEM peptides were classi-
ﬁed as AMPs. All the peptides equally displayed adequate charge for
an AMP, as the majority of natural AMPs have a net charge from +4
to +9 [29]. Hydrophobic ratios between 40%–60% have been found in
natural AMPs, and all CEM peptides are in this range with the exception
of CEM3 with a 33% hydrophobic ratio [29].
As antimicrobial prediction and key features were indicative of anti-
microbial activity by all designed CEM peptides, a screening of the pep-
tides was made in order to ﬁnd and study one or more short peptides
that could best preserve MSI-78 antimicrobial properties while provid-
ing indications on future strategies for the rational design of short, trun-
cated AMPs.
3.2. Antimicrobial characterization
MIC of MSI-78 and its 12-mer derivatives against S. aureus,
S. epidermidis, and P. aeruginosa are described in Table 2. Regarding
gram-positive bacteria, and as compared to the lead MSI-78 peptide,
the 12-mers lost activity against both S. aureus strains tested, indepen-
dently from their resistance to methicillin. Only the peptides that
cover the C-terminus of MSI-78 (CEM9, CEM10 and CEM11) showed
some antimicrobial activity at high concentrations against these
bacteria.
S. epidermidis was in general more susceptible to the 12-mers than
S. aureus strains, with several peptides having MIC values below
512 μg/mL. CEM1 with a MIC of 32–64 μg/mL was the most effective
12-mer against this bacterium.
Regarding the gram-negative bacteria P. aeruginosaMIC values dem-
onstrate that this strain is much more susceptible to the CEM 12-mers
and to MSI-78 than the tested gram-positive strains (Staphylococcus
strains), with some peptides having relatively low MIC (CEM1, CEM5,
CEM9, CEM10 and CEM11). As previously shown for S. epidermidis,
CEM1 was again the most effective peptide against P. aeruginosa with
a MIC of 4–8 μg/mL.MBC results (data not shown) were the same range or two fold
higher than MIC, indicating bactericidal effect of the peptides for the
concentrations tested.
Regarding the fungus strain, MSI-78 peptide did not show any effect
against C. albicans DMS 1386 at the concentrations tested, although
published data reports antifungal activity for MSI-78 [30]. Therefore
12-mer peptides were not tested against C. albicans.
MSI-78 activity was in general comparable to previously published
studies, being effective at low concentrations against S. aureus,
S. epidermidis and P. aeruginosa. MIC values obtained for MSI-78 against
S. aureus are in agreement with published data, results for S. epidermidis
and P. aeruginosa 27853 are slightly lower than published data, however
MIC of MSI-78 against these strains varies in the literature [9,11,30].
3.3. Cytotoxicity
Cytotoxicity studies were performed with CEM1, the selected AMP
that maintained high antimicrobial activity against P. aeruginosa and
S. epidermidis, and CEM2 that, despite differing only by 1 aa-shift from
the active peptide, had signiﬁcantly diminished antimicrobial activity.
CEM1 and CEM2were less cytotoxic to RBC than the reference AMP,
MSI-78 (Fig. 1). MSI-78 showed some toxicity at high concentrations
(53% hemolysis at 512 μg/mL, 25% hemolysis at 256 μg/mL and 13%
hemolysis at 128 μg/mL),which is in agreementwith data published be-
fore [31]. The short peptides, CEM1 and CEM2, showed no toxicity to
RBC even at the higher concentrations tested.
3.4. CD analysis
CD spectra of the parent peptide MSI-78, CEM1 and CEM2 in aque-
ous buffer exhibited a negative minimum at≈198 nm suggesting ran-
dom coil conformations. In the presence of DMPC LUV, spectra also
exhibit characteristic proﬁles of unordered peptides, pointing out to
no toxicity towards mammalian cells. In the presence of DMPG LUV,
two negative minima at≈208 nm and≈222 nm suggest the presence
ofα-helical conformations (Fig. 2). For all the peptides, results indicate a
transition from a random coil to an ordered secondary structure upon
interaction with the bacterial membrane mimetic system DMPG LUV.
In presence of DMPG LUV, calculated mean helix contents show differ-
ences between the peptides. The parent 22-mer peptide MSI-78 has
61%helicity, whereas helicity values around40–45% have been reported
by Mercke et al. for this peptide when bound to 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC) small unilamellar vesicles [32,
33]. For the 12-mers the mean helix content determined was 53% for
CEM1 and 35% for CEM2. This result shows a difference of about 20%
in the helix content between the two peptides, which may explain
their differential interaction with bacterial cells. Interestingly, while
having the same number and composition of aa, the only difference in
Fig. 1.Hemolytic activity of (A)MSI-78, (B) CEM1 and (C) CEM2 on human red blood cells. Peptide concentrations tested covered a range from 512 μg/mL to 1 μg/mL. Untreated bacterial
cells were used as negative control and bacterial cells treated with 0.2% Triton X-100 were used as positive control.
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which is at the N-terminus in CEM1 and at the C-terminus in CEM2.
Closer examination of the sequence shows that while the glycine in
CEM2 is positioned at the end of a densely positive charged region, in
CEM1 the glycine is at the end of a markedly hydrophobic region.
Additionally, glycine is known to have a good helix stabilizing effect at
the N-terminal of helices [34].
3.5. Hydrodynamic diameters and ζ-potential of LUV
The hydrodynamic diameters and ζ-potential of the LUV in the ab-
sence and in the presence of increasing concentrations of CEM1 and
CEM2 were evaluated (Fig. 3). Regarding their preparation, the size of
DMPC and DMPG LUV was approximately 100 nm. In the presence of
both peptides, DMPC LUV (Fig. 3A) exhibited a narrow size distribution
with amean diameter of approximately 80–110 nm,with a polidispersity
below 0.1, suggesting that the peptides do not inﬂuence the mammalian
cell membrane model even at high peptide concentration. However, the
interaction of both peptides with DMPG LUV (Fig. 3B) induced pro-
nounced changes on hydrodynamicmean diameters, especially at higher
peptide concentrations. In fact, the hydrodynamic mean diameters of
DMPG LUV in the presence of both peptides showed a heterogeneous
size distribution with a hydrodynamic mean diameter varying between
approximately 120 nm for 5 μM and 600 nm for 40 μM. The higher poly-
dispersity values (N0.15) obtained in association with the higher mean
diameter sizes for higher peptide concentrations point to the presence
of a heterogeneous population, and the presence of aggregates. In fact,
evaluation of the size distribution shows a small population of ~1.4 μm
(Supplement 1D), which reﬂects the presence of aggregates in the sam-
ple. This observation could be due to the aggregation of membrane-
bound peptide monomers, which has been reported to be associated to
the formation of a pore complex involved in the disruption of bilayers
[35]. The effect of the peptides on themembrane models was also evalu-
ated by studying the changes in the particles charge (Fig. 4). The zetaFig. 2. CD spectra of peptides CEM1 (dotted line), CEM2 (dashed line) and MSI-78 (solid line)
(C) 5 mM LUV, corresponding to a peptide:lipid molar ratio of 1:125.potential of DMPC LUV was−6 ± 4 mV (Fig. 4A). When the peptides
were present, the charge did not suffer signiﬁcant modiﬁcation
(Fig. 4A). On the other hand, the results obtained demonstrate a higher
charge variation for DMPG membrane model to more positive values
(Fig. 4B). In fact, the zeta potential of DMPG LUVwas−35±3mV, vary-
ing for more positive zeta potential values, reaching values of−18 ± 1
and−12 ± 2 mV for 40 μM of CEM1 and CEM2, respectively. These re-
sults support the establishment of electrostatic interactions between
the positively charged amino acids, namely lysine, and the polar head
groups of the phospholipids. In addition, it iswell-known that zeta poten-
tial is a powerful technique to quantify peptide:lipid interactions, being
the binding of theAMP to themembranemainly attributed to electrostat-
ic interactions between the peptide and the lipid head groups [36]. Re-
garding the similar variation of charge in the presence of DMPG LUV for
both peptides CEM1 and CEM2, substantial differences between the pep-
tides binding to the bacterial membrane are not expected.
3.6. LUV biophysical parameters
DLS using the count rate is a simple and reproducible technique to
determine the biophysical parameters of the membrane, including Tm
and cooperativity [28].
The biophysical parameters Tm and cooperativity of DMPC and
DMPG LUV were studied in the absence and in the presence of CEM1
and CEM2 at two distinct concentrations: a high peptide concentration,
40 μM, far above the MIC for CEM1 against P. aeruginosa ((4–8 μg/mL)/
(2.9–5.7 μM)) but still below theMIC for CEM2 ((128–265 μg/mL)/(94–
194 μM)) and a low peptide concentration, 7.3 μM, just above the MIC
for CEM1.
The analysis of Table 3, reveals that for high peptide concentrations
the Tm obtained is consistent with previous reported studies [20]. Re-
sults show that both peptides have a negligible inﬂuence on the DMPC
LUV main phase transition temperature. On the other hand, both pep-
tides have a wide effect on DMPG LUV biophysical properties, which is(40 μM) were acquired in aqueous buffer (A) and in the presence of DMPC (B) and DMPG
Fig. 3. Size and polydispersity index of DMPC (A) and DMPG (B) in the absence and in the presence of AMPs (5, 10, 20 and 40 μM).
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of DMPG LUV by roughly 3.0 °C. In the presence of CEM2, the effect on
membrane ﬂuidization is even more pronounced since the Tm remark-
ably drops approximately 7.0 °C. Furthermore, this result is followed
by a substantial decrease in the cooperativity of the lipid, indicating
that the peptide may form lipid patches due to the establishment of
electrostatic interactions with the negatively charged phospholipids of
the bacterial membrane model or it may be located buried in the lipid
bilayer (Table 3). These results, point to a more pronounced effect of
the less effective peptide (CEM2) on the biophysical properties of the
bacterial cell membrane model when high concentrations of peptide
are used. However, according to the in vitro biological assays conditions,
i.e., using a concentration of peptide slightly above the MIC of CEM1 for
P. aeruginosa, which is markedly lower than the experimental MIC ob-
tained for CEM2, provides evidence that CEM1 is the only peptide that
produces changes on the biophysical properties of the membrane
model (Table 4). In fact, CEM1 induces a lowering of the Tm correspond-
ing to a ﬂuidization of the membrane. Moreover, CEM1 at low concen-
tration decreases the cooperativity of the DMPG LUV main phase
transition, which may be related with the formation of lipid patches
and/or strong internalization of the peptide in the lipid bilayer. On the
other hand, in the presence of CEM2 the biophysical properties of the
bacterial membrane model only suffer a slight change in terms of
cooperativity of the main phase transition, with preservation of mem-
brane ﬂuidity.
4. Discussion
This study aimed at developing new short 12-mer AMP (CEM) de-
rived from the well-studied MSI-78 by following a strategy of reducingFig. 4. Zeta potential of DMPC (A) and DMPG LUV (B) in the absencthe size by truncating the C and/or N-termini spanning the entire pep-
tide by 1-aa shift. It has been previously shown that reasonable potency
and spectrum of activity could be attained by short AMPs in comparison
to longer ones [17,37–39]. According to the predictive algorithms, all
CEM peptides were classiﬁed as AMPs. This is correct for most peptides,
as they are active against P. aeruginosa with exception for CEM3 and
CEM7 for the tested concentrations. However for these peptides, predic-
tive tools do not seem to be suitable to foresee efﬁcient antimicrobial ac-
tivity for gram-positive bacteria.
Comparing the results obtained for the CEM dodecapeptides, it can
also be concluded that the C-terminal part of the peptide MSI-78 has
an important role in the antimicrobial activity as peptides covering
this region consistently displayed some antimicrobial activity. This
might be related to the high aliphatic index of these peptides.
Our studies show that shortening MSI-78 to a 12-mer peptide leads
in general to loss of antimicrobial activity, which is more pronounced
for gram-positive bacteria S. aureus, this effect is probably due to the
positive charge reduction, while MSI-78 has a net charge of +9, CEM
peptides have charges comprised between +4 and +6.
Nevertheless, CEM1, covering the ﬁrst 12 amino acids of the MSI-78
peptide, stood out as a good candidate to ﬁght P. aeruginosa infection
and potentially S. epidermidis infection. CEM1 was selective towards
bacteria as evaluated by hemolysis assays in agreement with an ob-
served preferential interaction towards negatively charged bacterial
membrane models, in contrast to the mammalian membrane models.
Interestingly, the shift of only one glycine from the ﬁrst position (N-ter-
minus) in CEM1 to the last position (C-terminus) in peptide CEM2 di-
minished antimicrobial activity signiﬁcantly. This was not expected, as
glycine is the smallest amino acid and not charged, being usually used
as spacer due to its neutrality. In addition, CEM1 and CEM2 do note and in the presence of CEM1 and CEM2 (5, 10, 20 and 40 μM).
Table 3
Values of main phase transition temperature (Tm) and cooperativity (B) determined by
DLS and obtained for DMPC and DMPG LUV (500 μM, pH 7.4) in the absence and in the
presence of AMPs (40 μM).
Tm Cooperativity (B)
DMPC 24.4 ± 0.2 347 ± 34
DMPC + CEM1 23.5 ± 0.6 254 ± 54
DMPC + CEM2 23.9 ± 1.2 217 ± 61
DMPG 24.1 ± 0.5 233 ± 5
DMPG + CEM1 20.8 ± 0.1 438 ± 54
DMPG + CEM2 16.7 ± 1.8 102 ± 11
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activity (Table 1). In order to understand their mechanism of action
CEM1and CEM2were studied regarding their interactionswithmamma-
lian and bacterial cell membrane models. Our studies show that both
peptides interact preferentially with the bacterial cell membrane models
(negatively charged LUV-DMPG), which is consistent with the cytotoxic-
ity studies. Concerning their distinct interaction with DMPG LUV, differ-
ences between CEM1 and CEM2 were only detected at low peptide
concentrations. In opposition to CEM2, CEM1 induced pronounced
changes on the biophysical parameters of DMPG LUV in a concentration
that is slightly above theMIC for P. aeruginosa. These results show that in-
teractions of CEM1 and CEM2withmembrane models are highly depen-
dent on peptide concentrations. This dependence on AMP concentration
related to the interaction with bacterial membranes strongly suggests
that bacterial membrane binding facilitates nucleation-dependent AMP
aggregation. This aggregation explains the largermean hydrodynamic di-
ameter obtained in the case of DMPG LUV for higher AMP concentrations.
Nevertheless, as the molar ratios peptide:lipid are not comparable be-
tween antimicrobial activity tests and biophysical studies with LUV, a
cautious analysis of the results has to be done.
A proposed mechanism for the interaction of CEM1 with bacterial
membranes initiates with peptide binding to the membrane surface
through electrostatic interactions, followed by the insertion of the posi-
tively charged residues into the interfacial region. Interaction of the pep-
tides with the bacterial membranes results in changes of the peptides
conformation from random coils to α-helices, causing local perturba-
tions in the phospholipid headgroup region of themembrane and conse-
quently bacterial cell death as previously described [40]. According to
this, for peptides with the same size, the disturbance in membrane for
the same AMP concentration will be higher with an increment of the
helix dynamics [40,41]. Therefore, the higher percentage of α-helical
conformation exhibited by CEM1 in contrast to CEM2will be responsible
for a more pronounced protein-phospholipid bacterial membrane inter-
action mediated by dynamic processes, for example, the rotational mo-
tion, wobbling, tilting, or bending of the helix [40]. The preferential
interaction with anionic vs zwitterionic lipids has been also demonstrat-
ed for the template peptide MSI-78 [42], which due to the electrostatic
interactions between the positively charged amino acids and the anionic
lipid headgroups may lead to peptide conformational changes, creating
hydrophobic patches in its structure, which favor the AMP insertion
within the lipid bilayers. This insertion and consequently bacterial mem-
brane model disruption was proven to be concentration-dependent as
well, as described in the case of MSI-78 [42].Table 4
Values of main phase transition temperature (Tm) and cooperativity (B) determined by
DLS and obtained for DMPC and DMPG LUV (500 μM, pH 7.4) in the absence and in the
presence of AMPs (7.3 μM).
Tm Cooperativity (B)
DMPG 24.1 ± 0.5 233 ± 5
DMPG + CEM1 21.4 ± 1.2 185 ± 10
DMPG + CEM2 23.1 ± 0.5 292 ± 62This study is also an attempt to understand structure–antimicrobial
activity relationship of designed AMPs. Other studies have addressed
the possible effects of shortening AMPs, Deslouches and co-workers
have reported that in peptides solely made from Arg and Val residues,
improved antimicrobial activity is dependent on peptide length and
conclude that a minimum length of 15 residues is required for signiﬁ-
cant antimicrobial activity [43]. These authors argue that hydrophilic
and hydrophobic regionswith increased length could explain the better
performance of longer peptides, which could be an explanation for the
loss of activity for the 12-mer MSI-78 derivatives. Zelezetsky and col-
leagues have shown that peptides as short as 14 residues lose their an-
timicrobial activity despite their adequate structure and sufﬁcient
charge [29]. In addition, shorter peptides could negatively inﬂuence
the formation of an α-helix, the conformation that MSI-78 acquires
when interacting with bacterial membranes. In fact, loss of propensity
to form helices has been associated to a reduction of peptides spectrum
of activity [43]. Overall, this study provides indications onpossible strat-
egies and consequences on the rational design of short, truncated pep-
tides. Speciﬁcally the importance of preserving secondary conformation
and exposition of positively charged residues.
As future perspective we could envisage the use of CEM1 in the
treatment of P. aeruginosa related infections such as cystic ﬁbrosis and
other infections caused by gram-negative bacteria.Acknowledgements
This work was ﬁnanced by FCT (Fundação para a Ciência e
Tecnologia) through Portuguese funds and funds provided by FEDER
through the Programa Operacional Factores de Competitividade (COM-
PETE) in the framework of the projects FCOMP-01-0124-FEDER-
009400 (PTDC/CTM/101484/2008), PEst-C/SAU/LA0002/2013, PEst-C/
QUI/UI0081/2013 and the grants: SFRH/BPD/79439/2011 (Claudia
Monteiro), SFRH/BPD/99124/2013 (Marina Pinheiro), SFRH/BD/72471/
2010 (Fabíola Costa) and SFRH/BD/89001/2012 (Catarina Seabra).
The authors would like to thank to Centro Hospitalar de São João,
EPE, Porto, for the human buffy coats.References
[1] A.J. Alanis, Resistance to antibiotics: are we in the post-antibiotic era? Arch. Med.
Res. 36 (2005) 697–705.
[2] E. Andres, J.L. Dimarcq, Cationic antimicrobial peptides: update of clinical develop-
ment, J. Intern. Med. 255 (2004) 519–520.
[3] J. Cruz, C. Ortiz, F. Guzman, R. Fernandez-Lafuente, R. Torres, Antimicrobial peptides:
promising compounds against pathogenic microorganisms, Curr. Med. Chem. 21
(20) (2014) 2299–2321.
[4] D. Fitzgerald-Hughes, M. Devocelle, H. Humphreys, Beyond conventional antibiotics
for the future treatment of methicillin-resistant Staphylococcus aureus infections:
two novel alternatives, FEMS Immunol. Med. Microbiol. 65 (2012) 399–412.
[5] F. Costa, I.F. Carvalho, R.C. Montelaro, P. Gomes, M.C. Martins, Covalent immobiliza-
tion of antimicrobial peptides (AMPs) onto biomaterial surfaces, Acta Biomater. 7
(2011) 1431–1440.
[6] J.P. Powers, R.E. Hancock, The relationship between peptide structure and antibacte-
rial activity, Peptides 24 (2003) 1681–1691.
[7] R.M. Epand, H.J. Vogel, Diversity of antimicrobial peptides and their mechanisms of
action, Biochim. Biophys. Acta 1462 (1999) 11–28.
[8] M.R. Yeaman, N.Y. Yount, Mechanisms of antimicrobial peptide action and resis-
tance, Pharmacol. Rev. 55 (2003) 27–55.
[9] Y. Ge, D.L. MacDonald, K.J. Holroyd, C. Thornsberry, H. Wexler, M. Zasloff, In vitro an-
tibacterial properties of pexiganan, an analog of magainin, Antimicrob. Agents
Chemother. 43 (1999) 782–788.
[10] B.A. Lipsky, K.J. Holroyd, M. Zasloff, Topical versus systemic antimicrobial therapy for
treating mildly infected diabetic foot ulcers: a randomized, controlled, double-
blinded,multicenter trial of pexiganan cream, Clin. Infect. Dis. 47 (2008) 1537–1545.
[11] L.M. Gottler, A. Ramamoorthy, Structure, membrane orientation, mechanism, and
function of pexiganan—a highly potent antimicrobial peptide designed from
magainin, Biochim. Biophys. Acta 1788 (2009) 1680–1686.
[12] M.G. Habets, M.A. Brockhurst, Therapeutic antimicrobial peptides may compromise
natural immunity, Biol. Lett. 8 (2012) 416–418.
[13] A. Tossi, L. Sandri, A. Giangaspero, Amphipathic, alpha-helical antimicrobial pep-
tides, Biopolymers 55 (2000) 4–30.
[14] R.E. Hancock, H.G. Sahl, Antimicrobial and host-defense peptides as new anti-
infective therapeutic strategies, Nat. Biotechnol. 24 (2006) 1551–1557.
1146 C. Monteiro et al. / Biochimica et Biophysica Acta 1848 (2015) 1139–1146[15] M. Pasupuleti, A. Schmidtchen, A. Chalupka, L. Ringstad, M. Malmsten, End-tagging
of ultra-short antimicrobial peptides by W/F stretches to facilitate bacterial killing,
PLoS ONE 4 (2009) e5285.
[16] M. Bastos, G. Bai, P. Gomes, D. Andreu, E. Goormaghtigh, M. Prieto, Energetics and
partition of two cecropin-melittin hybrid peptides to model membranes of different
composition, Biophys. J. 94 (2008) 2128–2141.
[17] D. Andreu, J. Ubach, A. Boman, B. Wahlin, D. Wade, R.B. Merriﬁeld, H.G. Boman,
Shortened cecropin A-melittin hybrids. Signiﬁcant size reduction retains potent an-
tibiotic activity, FEBS Lett. 296 (1992) 190–194.
[18] O.G. Mouritsen, Model answers to lipid membrane questions, Cold Spring Harbor
Perspect. Biol. 3 (2011) a004622.
[19] R.M. Hatﬁeld, L.W. Fung, Molecular properties of a stratum corneum model lipid
system: large unilamellar vesicles, Biophys. J. 68 (1995) 196–207.
[20] M. Pinheiro, M. Arede, C. Nunes, J.M. Caio, C. Moiteiro, M. Lucio, S. Reis, Differential
interactions of rifabutin with human and bacterial membranes: implication for its
therapeutic and toxic effects, J. Med. Chem. 56 (2013) 417–426.
[21] N. Ilic, M. Novkovic, F. Guida, D. Xhindoli, M. Benincasa, A. Tossi, D. Juretic, Selective
antimicrobial activity and mode of action of adepantins, glycine-rich peptide antibi-
otics based on anuran antimicrobial peptide sequences, Biochim. Biophys. Acta 1828
(2013) 1004–1012.
[22] S.C. Lopes, C. Ribeiro, P. Gameiro, A new approach to counteract bacteria resistance:
a comparative study between moxiﬂoxacin and a new moxiﬂoxacin derivative in
different model systems of bacterial membrane, Chem. Biol. Drug Des. 81 (2013)
265–274.
[23] R.M. Epand, R.F. Epand, Domains in bacterial membranes and the action of antimi-
crobial agents, Mol. BioSyst. 5 (2009) 580–587.
[24] M. Brandt, S. Gammeltoft, K. Jensen, Microwave heating for solid-phase peptide syn-
thesis: general evaluation and application to 15-mer phosphopeptides, Int. J. Pept.
Res. Ther. 12 (2006) 349–357.
[25] I. Wiegand, K. Hilpert, R.E. Hancock, Agar and broth dilution methods to determine
theminimal inhibitory concentration (MIC) of antimicrobial substances, Nat. Protoc.
3 (2008) 163–175.
[26] P. Luo, R.L. Baldwin, Mechanism of helix induction by triﬂuoroethanol: a framework
for extrapolating the helix-forming properties of peptides from triﬂuoroethanol/
water mixtures back to water, Biochemistry 36 (1997) 8413–8421.
[27] F. Barbato, G. di Martino, L. Grumetto, M.I. La Rotonda, Prediction of drug–mem-
brane interactions by IAM-HPLC: effects of different phospholipid stationary phases
on the partition of bases, Eur. J. Pharm. Sci. 22 (2004) 261–269.
[28] N. Michel, A.S. Fabiano, A. Polidori, R. Jack, B. Pucci, Determination of phase transi-
tion temperatures of lipids by light scattering, Chem. Phys. Lipids 139 (2006) 11–19.[29] I. Zelezetsky, A. Tossi, Alpha-helical antimicrobial peptides—using a sequence tem-
plate to guide structure–activity relationship studies, Biochim. Biophys. Acta 1758
(2006) 1436–1449.
[30] N.P. Chongsiriwatana, T.M. Miller, M. Wetzler, S. Vakulenko, A.J. Karlsson, S.P.
Palecek, S. Mobashery, A.E. Barron, Short alkylated peptoid mimics of antimicrobial
lipopeptides, Antimicrob. Agents Chemother. 55 (2011) 417–420.
[31] Y. Zhang, H. Zhao, G.Y. Yu, X.D. Liu, J.H. Shen, W.H. Lee, Structure–function relation-
ship of king cobra cathelicidin, Peptides 31 (2010) 1488–1493.
[32] A. Mecke, D.K. Lee, A. Ramamoorthy, B.G. Orr, M.M. Banaszak Holl, Membrane thin-
ning due to antimicrobial peptide binding: an atomic force microscopy study of
MSI-78 in lipid bilayers, Biophys. J. 89 (2005) 4043–4050.
[33] A. Ramamoorthy, S. Thennarasu, D.K. Lee, A. Tan, L. Maloy, Solid-state NMR investi-
gation of the membrane-disrupting mechanism of antimicrobial peptides MSI-78
and MSI-594 derived from magainin 2 and melittin, Biophys. J. 91 (2006) 206–216.
[34] J.S. Richardson, D.C. Richardson, Amino acid preferences for speciﬁc locations at the
ends of alpha helices, Science 240 (1988) 1648–1652.
[35] S. Thennarasu, D.K. Lee, A. Tan, U. Prasad Kari, A. Ramamoorthy, Antimicrobial activ-
ity and membrane selective interactions of a synthetic lipopeptide MSI-843,
Biochim. Biophys. Acta 1711 (2005) 49–58.
[36] J.M. Freire, M.M. Domingues, J. Matos, M.N. Melo, A.S. Veiga, N.C. Santos, M.A.
Castanho, Using zeta-potential measurements to quantify peptide partition to
lipid membranes, Eur. Biophys. J. 40 (2011) 481–487.
[37] H. Ulvatne, S. Karoliussen, T. Stiberg, O. Rekdal, J.S. Svendsen, Short antibacterial
peptides and erythromycin act synergically against Escherichia coli, J. Antimicrob.
Chemother. 48 (2001) 203–208.
[38] S.Y. Shin, K.S. Hahm, A short alpha-helical antimicrobial peptide with antibacterial
selectivity, Biotechnol. Lett. 26 (2004) 735–739.
[39] W.L. Zhu, K.S. Hahm, S.Y. Shin, Cell selectivity and mechanism of action of short an-
timicrobial peptides designed from the cell-penetrating peptide Pep-1, J. Pept. Sci.
15 (2009) 569–575.
[40] M.A. Kol, A.I. de Kroon, J.A. Killian, B. de Kruijff, Transbilayer movement of phospho-
lipids in biogenic membranes, Biochemistry 43 (2004) 2673–2681.
[41] C.C. Forbes, K.M. DiVittorio, B.D. Smith, Bolaamphiphiles promote phospholipid
translocation across vesicle membranes, J. Am. Chem. Soc. 128 (2006) 9211–9218.
[42] P. Yang, A. Ramamoorthy, Z. Chen,Membraneorientation ofMSI-78measured by sum
frequency generation vibrational spectroscopy, Langmuir 27 (2011) 7760–7767.
[43] B. Deslouches, S.M. Phadke, V. Lazarevic, M. Cascio, K. Islam, R.C. Montelaro, T.A.
Mietzner, De novo generation of cationic antimicrobial peptides: inﬂuence of length
and tryptophan substitution on antimicrobial activity, Antimicrob. Agents
Chemother. 49 (2005) 316–322.
